ClinicalTrials.gg
RecruitingNCT07828496Updated Sep 18, 2026

Cognitive Rehabilitation Using Neurofeedback With Brain-computer Interface

An interventional study of Brain-computer interface with neurofeedback with 3D game sessions in Acquired Brain Injury Including Stroke and Epilepsy, sponsored by KK Women's and Children's Hospital. Recruiting at 1 site in Singapore. Open to participants aged 7 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by KK Women's and Children's Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2025, registered Sep 2026).
  • Started Nov 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
7 Years to 21 Years
Sex
All
01

Study summary

The goal of this clinical trial is to determine whether a Brain-Computer Interface Neurofeedback Training (BCI-NFT) programme can improve cognitive outcomes, and whether electroencephalography (EEG)-based measures can serve as objective markers of cognitive impairment, in children and adolescents aged 7 to 21 years with acquired brain injury (ABI), including traumatic brain injury (TBI), stroke, encephalitis, brain tumour, or epilepsy.

A group of children and adolescents aged 7 to 21 years without any history of brain injury or epilepsy will also be enrolled to provide normative EEG data for comparison.

The main questions the study aims to answer are:

  1. Can EEG-derived measures of sustained attention, relaxation, and selective attention detect and quantify cognitive impairment in children and adolescents following ABI?
  2. Does a structured BCI-NFT programme improve cognitive and behavioural outcomes, including attention, memory, and executive function, compared with standard care alone?

Researchers will compare an Intervention Group, who will receive BCI-NFT in addition to standard cognitive rehabilitation, with a Waitlist-Control Group, who will initially receive standard care alone before subsequently crossing over to receive BCI-NFT. This design will allow researchers to determine whether BCI-NFT leads to greater improvements in cognitive and behavioural outcomes compared with standard care alone.

Participants in the main ABI cohort will:

  • Complete behavioural assessments using the Behavior Assessment System for Children, Third Edition (BASC-3), including parent and/or teacher reports.
  • Complete 12 BCI-NFT sessions over a 10-week period. Each session will last approximately 60 minutes. During each session, participants will wear a wireless EEG headset and interact with neurofeedback computer games designed to respond to their sustained attention, selective attention, and response time.
  • Repeat the BASC-3 behavioural assessments at the end of the study period.
  • Have undergone a recent neuropsychological assessment within the preceding 2 years and ongoing review by a neuropsychologist.

Participants in the normative EEG cohort, comprising children and adolescents without a history of brain injury or epilepsy, will attend a single study session. During this session, EEG activity will be recorded both at rest and while participants interact with a three-dimensional (3D) computer game. These recordings will provide normative EEG data against which findings from participants with ABI can be compared.

02

Conditions studied

  • Acquired Brain Injury Including Stroke
  • Epilepsy

Browse trials for

03

In context

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 422 are open to participants now.

This study's planned enrollment of 70 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

KK Women's and Children's Hospital is the lead sponsor of 137 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Normaitve cohort:

- Patients with no history of epilepsy

Inclusion criteria

Inclusion Criteria:

  • Post acquired brain injury (stroke, encephalitis, brain tumour, traumatic brain injury)
  • Epilepsy

Exclusion criteria

Exclusion Criteria:

  • History of photosensitive seizures
  • Diagnosis of intellectual disability
  • Presence of psychotic symptoms
  • Diagnosis of attention deficit and hyperactivity disorder
  • Diagnosis of autism spectrum disorder
  • Children on methylphenidate
  • Children who are unable to cooperate with neuropsychological assessment of cognitive function
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    BCI

    Intervention then standard of care

    Other: Brain-computer interface with neurofeedback with 3D game sessions

  • Experimental
    Usual care

    Usual care followed by intervention

    Other: Brain-computer interface with neurofeedback with 3D game sessions

Interventions

  • OtherBrain-computer interface with neurofeedback with 3D game sessions

    12 sessions of BCI-NFT computer games over 10 weeks

    Also known as: BCI-NFT

06

What researchers measure

Primary outcomes

  1. Change in Attention Threshold

    Change in the game's adaptive attention threshold value, measured at each session, on a normalised scale between 0 to 1, where the greater value indicates greater sustained attention.

    Time frame: Baseline (Session 1) to final session (Session 12), over 10 weeks

  2. Change in Relaxation Threshold

    Change in the game's adaptive threshold value, measured at each session, according to the normalised scale between 0 and 1, where higher value means greater sustained relaxation.

    Time frame: Baseline (Session 1) to final session (Session 12), over 10 weeks

  3. Change in Response Time

    Change in mean response time to in-game stimuli, measured in milliseconds, at each session.

    Time frame: Baseline (Session 1) to final session (Session 12), over 10 weeks

  4. Change in Alpha-Lateralization Index

    Change in the alpha-lateralization index, a unitless measure derived from posterior EEG channels (P7/P8, O1/O2), ranging from -1 to +1, measured at each session.

    Time frame: Baseline (Session 1) to final session (Session 12), over 10 weeks

  5. Change in Beta-to-Alpha Power Ratio

    Change in the ratio of EEG beta-band to alpha-band spectral power, a unitless ratio, measured at each session.

    Time frame: Baseline (Session 1) to final session (Session 12), over 10 weeks

Secondary outcomes

  1. Internalising problem score on Behavior Assessment System for Children, Third Edition (BASC-3)

    Total internalising symptoms (anxiety, depression, somatisation) on BASC-3 questionnaire. T-scores for the BASC-3 Internalizing Problems composite range from a minimum of 20 to a maximum of 120. Higher scores indicate greater severity of mood disorder.

    Time frame: From enrollment to 20 weeks

  2. Externalising symptoms score in Behavior Assessment System for Children, Third Edition (BASC-3)

    Degree of change in total score for externalising symptoms (Hyperactivity, aggression, conduct problems) in BASC-3 questionnaire. Raw score will be converted to T-score with range from 20 to 120. Higher score suggests a high level of maladjustment or severe impairment

    Time frame: From enrollment to end of study 20 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Consent for sharing of individual patient data was not obtained from participants

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2028, 27 months after the start.

Of 337 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 27 months is below that.

Counting every sponsor, half of 358 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 18, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Feb 1, 2028
CompletionEst.
Jun 30, 2028
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07828496
Responsible party
Teo Jia Hui (Clinical Assistant Professor, KK Women's and Children's Hospital) — Principal investigator
First posted
Sep 18, 2026
Start date
Nov 1, 2025
Primary completion
Feb 1, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 18, 2026

Study contacts

Jia Hui Teo
Contact
teo.jia.hui@singhealth.com.sg
+6563926042

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion